# 3 Observable trends:

1. Looking at the bar graphs plotted, we can safely say that the study was fair as there are roughly the same number of mice in each study. Unfortunately, there was a duplicate mouse (Mouse ID g989) that had to be completely deleted as using one drug regiment over another would be considered unjust as there is no good reason to use one over the other not knowing the reason behind the duplicate (e.g., wrong ID could be entered by data set creator). The number of mice is also roughly equal, with 123 females and 125 males. This number would have been more closely comparable had the duplicate mouse data been clean as Mouse g989 was a female.
2. The Infubinol Drug Regimen performed the poorest as mice in this group have on average one of the highest final tumor volumes. The data is also the most varied as it is the only regimen that has an outlier.
3. Looking at Capomulin data, on average the heavier the mouse, the bigger the tumor. The is a strong positive correlation (0.84) to support this statement. By taking one mouse in the Capomulin (Mouse ID s185) we can see that the general trend over time is a reduction in tumor size. Seeing this trend graphed will all mice will allow us to come to the conclusion that Capomulin has been a successful Drug Regimen, although this can definitely be said for mouse s185.S